Comparative Pharmacology
Head-to-head clinical analysis: NEO FRADIN versus SATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO FRADIN versus SATRIC.
NEO-FRADIN vs SATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. It also disrupts bacterial cell membrane integrity.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
50-100 mg/kg/day orally in 3-4 divided doses. Maximum 3 g/day.
No standard dosing information available for SATRIC.
None Documented
None Documented
2-3 hours in normal renal function; prolonged to 24-30 hours in anuria or severe renal impairment; no significant change in hepatic disease.
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Renal: >90% unchanged drug via glomerular filtration, with small amount reabsorbed; biliary/fecal: <2%.
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Category C
Category C
Antibiotic
Antiprotozoal, Antibiotic